Renal masses: 10-year data support RFA for tumors <3 cm

  • Johnson B & al.
  • J Urol
  • 28 Aug 2018

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Long-term data support radiofrequency ablation (RFA) as an effective treatment option in patients with small renal masses (size,
  • RFA yielded good oncologic outcomes at 10 years, and no recurrence was developed after 5 years.

Why this matters

  • 10-year data are consistent with the current recommendations for renal tumors

Study design

  • Study of 106 patients (112 renal tumors) who underwent radiofrequency ablation during 2000-2007.
  • Funding: None.

Key results

  • 112 tumors were treated with radiofrequency ablation.
  • Median follow-up duration was 79 months; 65 patients had ≥10 years follow-up.
  • Mean tumor size was 2.5 cm.
  • Mean tumor size in the recurrence group was 3.2 cm, and for patients without recurrence it was 2.4 cm (P=.005).
  • At 6 years, DFS was 89%, 6-year cancer-specific survival (CSS) was 96%, and metastasis-free survival was 96%.
  • At 6 years, patients with tumor size
  • In 65 patients with ≥10-year follow-up, DFS, CSS, and OS were 81.5%, 94%, and 49%, respectively.
  • 80% recurrences occurred in patients with tumors ≥3 cm.
  • No recurrence occurred after 5 years.

Limitations

  • Retrospective design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit